X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cardiac & cardiovascular systems (9) 9
humans (7) 7
index medicus (7) 7
acute coronary syndrome (6) 6
ezetimibe (6) 6
female (6) 6
male (6) 6
prospective studies (6) 6
therapy (6) 6
aged (5) 5
pitavastatin (5) 5
cardiovascular (4) 4
density-lipoprotein cholesterol (4) 4
drug therapy, combination (4) 4
follow-up studies (4) 4
lipid-lowering (4) 4
middle aged (4) 4
acute coronary syndrome - complications (3) 3
acute myocardial-infarction (3) 3
clinical trial (3) 3
combination therapy (3) 3
japan (3) 3
risk (3) 3
abridged index medicus (2) 2
acute coronary syndrome - blood (2) 2
acute coronary syndrome - drug therapy (2) 2
anticholesteremic agents (2) 2
anticholesteremic agents - administration & dosage (2) 2
atorvastatin (2) 2
cardiovascular disease (2) 2
cardiovascular events (2) 2
cholesterol, ldl - blood (2) 2
confidence intervals (2) 2
coronary artery disease (2) 2
coronary artery disease - complications (2) 2
coronary heart disease (2) 2
coronary vessels (2) 2
dose-response relationship, drug (2) 2
early statin treatment (2) 2
ezetimibe - administration & dosage (2) 2
glomerular filtration rate (2) 2
glomerular filtration rate - physiology (2) 2
heart attacks (2) 2
heart institute (2) 2
heart-disease (2) 2
high blood-pressure (2) 2
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (2) 2
hypertension (2) 2
hypertension - complications (2) 2
hypertension - drug therapy (2) 2
incidence (2) 2
lipids (2) 2
myocardial infarction (2) 2
myocardial-infarction (2) 2
peripheral vascular disease (2) 2
prognosis (2) 2
quinolines - administration & dosage (2) 2
randomized-trial (2) 2
risk factors (2) 2
serum creatinine (2) 2
sitosterol (2) 2
stroke (2) 2
studies (2) 2
time factors (2) 2
treatment outcome (2) 2
acute coronary syndrome - diagnostic imaging (1) 1
acute coronary syndrome - mortality (1) 1
acute coronary syndrome - prevention & control (1) 1
acute coronary syndromes (1) 1
acute-myocardial-infarction (1) 1
aged, 80 and over (1) 1
although intensive lowering with standard pitavastatin plus ezetimibe showed no more cardiovascular benefit than standard pitavastatin monotherapy in acs patients with dyslipidaemia (1) 1
amlodipine (1) 1
amlodipine - administration & dosage (1) 1
amlodipine - adverse effects (1) 1
analysis and chemistry (1) 1
angina (1) 1
angina pectoris (1) 1
angina, unstable - drug therapy (1) 1
angina, unstable - mortality (1) 1
angiography (1) 1
angiotensin receptor antagonists - administration & dosage (1) 1
angiotensin receptor antagonists - adverse effects (1) 1
angiotensin-aldosterone system (1) 1
anticholesteremic agents - adverse effects (1) 1
antihypertensive agents - therapeutic use (1) 1
artery-disease (1) 1
association task-force (1) 1
atherosclerosis (1) 1
benzimidazoles - administration & dosage (1) 1
benzimidazoles - adverse effects (1) 1
biomarkers - blood (1) 1
blood (1) 1
blood pressure (1) 1
blood pressure - physiology (1) 1
c-reactive protein (1) 1
c-reactive protein - metabolism (1) 1
calcium channel blockers - administration & dosage (1) 1
calcium channel blockers - adverse effects (1) 1
calcium-channel blockers (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Ogawa, H and Koyanagi, R and Kawada-Watanabe, E and Yamaguchi, J and Takagi, A and Hagiwara, N and Deedwania, P. C and Demicco, D. A and Breazna, A and Wun, C. C and Pedersen, T and Colhoun, H. M and Neil, A and Hitman, G and Nakanishi, K and Fukuda, S and Shimada, K and Ehara, S and Inanami, H and Matsumoto, K and Taguchi, H and Muro, T and Yoshikawa, J and Yoshiyama, M and Dimitriadis, K and Tsioufis, C and Tatsis, I and Chlapoutakis, G and Lioni, L and Tzamou, V and Kasiakogias, A and Thomopoulos, C and Tousoulis, D and Stefanadis, C and Terentes-Printzios, D and Vlachopoulos, C and Aznaouridis, K and Ioakeimidis, N and Parapid, B and Vukcevic, V and Obrenovic-Kircanski, B and Simic, D. V and Milic, N. M and Stojanov, V and Beleslin, B and Nedeljkovic, I and Nedeljkovic-Arsenovic, O. M. S and Ostojic, M. C and Kotecha, D and Krum, H and New, G and Eccleston, D and Collins, P and Flather, M and Pepper, J and Tomiyama, H and Odaira, M and Yoshida, M and Shiina, K and Matsumoto, C and Yamashina, A and Pastormerlo, L. E and Maffei, S and Chubuchny, V and Mazzone, A. M and Susini, C and Passino, C and Chiappino, D and Emdin, M and Clerico, A and Katsi, V and Souretis, G and Vlasseros, I and Vrachatis, D and Kallikazaros, I and Androulakis, E and Chatzistamatiou, E and Papageorgiou, N and Miliou, A and Siasos, G and Moustakas, G and Ochoa, J. E and Balparda, J. K and Correa, M. M and Valencia, A. M and Alvarez, M and Mcewen, J. G and Bilo, G and Salvi, P and Aristizabal, D and Parati, G and De Vries, H and Engen-Verheul, M and Kemps, H. M. C and Kraaijenhagen, R and Peek, N and Vervueren, P. L and Bongard, V and Arveiler, D and Dallongeville, J and ... and on behalf of GEMI Group and on behalf of Korean Acute Myocardial Infarction Registry and on behalf of SWEETHEART-Study-Group and on behalf of QuIK Steering Committee and on behalf of On Behalf of the MADIT-CRT Investigators and on behalf of NAGOYA HEART Study Group and on behalf of Kan Wang, Xiaosheng Hu, Changqing Du, Shike Tu, Furong Zhang, and Xudong Xie and on behalf of The FRANCE2 scientific Committee and on behalf of Oslo Ischemia Study Group and on behalf of EUROVISION investigators and on behalf of German transcatheter aortic valve interventions registry and on behalf of Tokyo CCU network Committee and on behalf of Neha Singh and on behalf of the CASE-J Ex Study Group and on behalf of On behalf of Preserved-DATA-HELP (Diagnostic And TherApeutic methods, used in patients with systolic HEart failure, Living in Poland) investigators and on behalf of Associazione per lo Studio della Trombosi in Cardiologia and on behalf of BRAVO Investigators and on behalf of TIMI Study Group and on behalf of The Swedish Heart Failure Registry and on behalf of German Competence Network of Heart Failure and on behalf of Nordic ARVC Registry and on behalf of ACUITY and HORIZONS AMI and on behalf of Biomarkers in Cardiology and on behalf of Portuguese Registry of Acute Coronary Syndromes Investigators and on behalf of IMPROVE study group and on behalf of CLARICOR and on behalf of Department of Cardiology, Jinan Central Hospital Affiliated to Shandong University and on behalf of STAR-Study-Group and on behalf of DiaRegis-Study-Group and on behalf of MASS II Trial and on behalf of The Rotterdam Study and on behalf of the Korea Acute Myocardial Infarction Registry and on behalf of SACRA and PLUM registries investigators and on behalf of SMILE-4 and on behalf of AMIS Plus Investigators and on behalf of Gutenberg Heart Study and on behalf of VIPER-BP Study Investigators and on behalf of Hypersleep and on behalf of The CHART-2 Investigators and on behalf of HIJ-CREATE and on behalf of Joint "Croix Rouge Francaise" and "Federation Francaise de Cardiologie" Study Investigators and on behalf of ACTION and on behalf of EHS-PCI-Registry Study Group and on behalf of CCMR-3B Study Investigators and on behalf of The EURIKA investigators and on behalf of The GARFIELD Investigators and on behalf of a name and on behalf of RESET study investigators and on behalf of the SchlaHF-Investigators and on behalf of VIPER-BP Investigators and on behalf of ISSUE3 investigators and on behalf of FOCUS registry investigators and on behalf of NEO study and on behalf of cardiology unit, Ramathibodi hospital and on behalf of First Division of Cardiovascular Department, Chang Gung Memorial Hospital, Linkou and on behalf of Kyoto University/Canon joint research project and on behalf of The REACH registry investigators and on behalf of GCKD Study Investigators and on behalf of College National des Cardiologues des Hopitaux francais and on behalf of BBK registry Bad Krozingen and on behalf of PL-ACS Investigators and on behalf of the Three-City study Group and on behalf of Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation and on behalf of ARISTOTLE Investigators and Committees and on behalf of Heart Cycle and on behalf of Electrophysiologist International Community "EPIC" Alliance and on behalf of MOMOTARO study and on behalf of BOREAS-TCM study and on behalf of BIOSOLVE-I Investigators and on behalf of On behalf of DATA-HELP study (Diagnostic And TherApeutic methods, used in patients with systolic HEart failure, Living in Poland) investigators and on behalf of FINN-AKVA study group
European Heart Journal, ISSN 0195-668X, 08/2012, Volume 33, Issue suppl 1, pp. 655 - 939
Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 12/2018, Volume 122, Issue 11, pp. 1817 - 1823
The systematic inflammatory response might confound renal impairment, and both have been reported to affect clinical outcomes after acute coronary syndrome. We... 
SERUM CREATININE | DENSITY-LIPOPROTEIN CHOLESTEROL | IMPACT | CARDIAC & CARDIOVASCULAR SYSTEMS | INFLAMMATION | DISEASE | HEART-INSTITUTE | LONG-TERM MORTALITY | OUTCOMES | PRIMARY ANGIOPLASTY | ACUTE-MYOCARDIAL-INFARCTION | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Single-Blind Method | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Male | Quinolines - administration & dosage | Glomerular Filtration Rate - physiology | Dose-Response Relationship, Drug | Acute Coronary Syndrome - complications | C-Reactive Protein - metabolism | Renal Insufficiency - physiopathology | Time Factors | Cholesterol, LDL - blood | Female | Renal Insufficiency - complications | Drug Therapy, Combination | Ezetimibe - administration & dosage | Biomarkers - blood | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - administration & dosage | Aged | Myocardial infarction | Therapy | Renal function | C-reactive protein | Heart attacks | Heart surgery | Impairment | Lipids | Inflammatory response | Cardiovascular disease | Angina | Clinical outcomes | Proteins | Confidence intervals | Electrocardiography | Statins | Cerebral infarction | Stroke | Filtration | Inflammation | Angina pectoris | Patients | Glomerular filtration rate | Family physicians | Studies | Sensitivity | Hospitals | Medical prognosis | Coronary vessels | Infarction | Diabetes | Acute coronary syndromes
Journal Article
Journal Article
JOURNAL OF THE AMERICAN HEART ASSOCIATION, ISSN 2047-9980, 08/2019, Volume 8, Issue 16, p. e012953
Background-This study aimed to examine the impact of baseline eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio on clinical outcomes of patients with... 
TRIAL | eicosapentaenoic acid | DENSITY-LIPOPROTEIN CHOLESTEROL | HEART-DISEASE | CARDIAC & CARDIOVASCULAR SYSTEMS | acute coronary syndrome | THERAPY | STATIN | RISK | cholesterol-lowering drugs | EZETIMIBE | PLAQUE
Journal Article
Journal of Cardiology, ISSN 0914-5087, 2016, Volume 69, Issue 3, pp. 536 - 541
Journal Article
Journal of Cardiology, ISSN 0914-5087, 2013, Volume 62, Issue 4, pp. 217 - 223
Journal Article
Circulation, ISSN 0009-7322, 11/2018, Volume 138, Issue Suppl_1 Suppl 1, pp. A11576 - A11576
IntroductionThere were few reports examining the difference of treatment effect of lipid lowering therapy by ezetimibe in accordance with baseline low-density... 
Journal Article
European heart journal, ISSN 0195-668X, 08/2017, Volume 38, Issue 29, pp. 2264 - 2276
To elucidate the effects of intensive LDL-C lowering treatment with a standard dose of statin and ezetimibe in patients with dyslipidaemia and high risk of... 
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Dyslipidemias - mortality | Prospective Studies | Dyslipidemias - complications | Follow-Up Studies | Humans | Acute Coronary Syndrome - mortality | Non-ST Elevated Myocardial Infarction - complications | Male | Quinolines - administration & dosage | Dose-Response Relationship, Drug | Acute Coronary Syndrome - complications | Angina, Unstable - drug therapy | Female | Drug Therapy, Combination | Dyslipidemias - drug therapy | ST Elevation Myocardial Infarction - complications | Ezetimibe - adverse effects | Angina, Unstable - mortality | Kaplan-Meier Estimate | ST Elevation Myocardial Infarction - drug therapy | Cholesterol, LDL - drug effects | Treatment Outcome | Ezetimibe - administration & dosage | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | ST Elevation Myocardial Infarction - mortality | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Anticholesteremic Agents - administration & dosage | Cholesterol, LDL - metabolism | Aged | Non-ST Elevated Myocardial Infarction - drug therapy | Non-ST Elevated Myocardial Infarction - mortality | Quinolines - adverse effects | Pitavastatin | Clinical Research | Editor's Choice | Ezetimibe | Clinical trial | Lipid-lowering | Combination therapy | Acute coronary syndrome
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.